KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Leases: 2018-2025

Historic Operating Leases for Teva Pharmaceutical Industries (TEVA) over the last 7 years, with Sep 2025 value amounting to $283.0 million.

  • Teva Pharmaceutical Industries' Operating Leases fell 4.07% to $283.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $283.0 million, marking a year-over-year decrease of 4.07%. This contributed to the annual value of $296.0 million for FY2024, which is 29.02% down from last year.
  • According to the latest figures from Q3 2025, Teva Pharmaceutical Industries' Operating Leases is $283.0 million, which was down 4.39% from $296.0 million recorded in Q2 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Operating Leases peaked at $525.0 million during Q4 2021, and registered a low of $281.0 million during Q2 2024.
  • For the 3-year period, Teva Pharmaceutical Industries' Operating Leases averaged around $314.3 million, with its median value being $296.0 million (2025).
  • In the last 5 years, Teva Pharmaceutical Industries' Operating Leases rose by 7.30% in 2021 and then dropped by 29.02% in 2024.
  • Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Operating Leases stood at $525.0 million in 2021, then fell by 15.81% to $442.0 million in 2022, then decreased by 5.66% to $417.0 million in 2023, then dropped by 29.02% to $296.0 million in 2024, then decreased by 4.07% to $283.0 million in 2025.
  • Its Operating Leases stands at $283.0 million for Q3 2025, versus $296.0 million for Q2 2025 and $288.0 million for Q1 2025.